NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
Open Posted
- Opportunity number
- RFA-HL-26-002
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- 501(c)(3) Nonprofits
- Small Businesses
- Public or Indian Housing Auth.
- County Governments
- Higher Education Inst. (Private)
- Higher Education Inst. (Public)
- City/Township Governments
- Tribal Organizations (Not Federally Recognized)
- Other
- For Profit Organizations
- Non-501(c)(3) Nonprofits
- Independent School Districts
- State Governments
- Special District Governments
- Tribal Governments (Federally Recognized)
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health National Heart, Lung, and Blood Institute (NHLBI) seeks applicants for the Outstanding Investigator Award (R35 Clinical Trial Optional) with an application due date of April 28, 2027. This award requires applicants to be current PDs/PIs on at least two NHLBI R01-equivalent awards, establishing a restrictive eligibility gate that significantly narrows the candidate pool.
Eligible applicant categories include 501(c)(3) nonprofits, public and private higher education institutions, small businesses, state and local governments, tribal organizations (both federally and non-federally recognized), for-profit organizations, and other nonprofit entities. Non-domestic entities and foreign components of U.S. organizations are ineligible; however, foreign components as defined in the NIH Grants Policy Statement are permitted.
The OIA provides up to seven years of support and is designed to serve as the primary and most likely sole source of NHLBI funding on individual grant awards. The program emphasizes long-term stability, reduced grant-writing burden, and increased research flexibility by freeing investigators from specific aims proposed in advance. Research must remain within NHLBI's mission scope covering heart, lung, blood, and sleep disorders. The award prioritizes investigators with outstanding records demonstrating ability to make major contributions to HLBS research and aims to enable greater risk-taking, pursuit of longer-timeframe investigations, and commitment to mentoring and scientific service.
Applications undergo initial review by an appropriate study section followed by secondary review by the National Heart, Lung, and Blood Advisory Council, with typical review timelines of seven to nine months. The opportunity is assigned to multiple Assistance Listing parent programs including Cardiovascular Diseases Research (CFDA 93.837), Lung Diseases Research (CFDA 93.838), Blood Diseases and Resources Research (CFDA 93.839), Translation and Implementation Science Research (CFDA 93.840), and National Center on Sleep Disorders Research (CFDA 93.233).
Synopsis
The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PDs/PIs) who are currently PDs/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PDs/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission (https://www.nhlbi.nih.gov/about/mission-statement). It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PDs/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate commitment of PDs/PIs to research through increased stability of funding; and Enable PDs/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Files
| File | Type | Posted |
|---|---|---|
| PKG00289028.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity